The development of alcohol dependence is associated with significant morbidity and mortality. For the majority of affected people the most appropriate goal, in terms of drinking behaviour, is abstinence from alcohol. Psychosocial intervention is the mainstay of the treatment but adjuvant pharmacotherapy is also available and its use recommended.
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In 2014/5, there were an estimated 1.1 million alcohol-related hospital admission in England, representing a 115% increase over 2003/4. 4, 5 A total of 8697 wholly attributable alcohol-related deaths were registered in the UK during 2014, two-thirds of which were attributed to alcohol-related liver disease. 6 However, a considerably higher estimate of 25 332 can be extrapolated from data provided by Public Health England based on a combination of all deaths relating to alcohol-specific conditions together with those where alcohol was causally implicated in some but not all cases. 7 The estimated cost of alcohol misuse to the National Health Service (NHS) is £3.5 billion per annum, while the overall costs of alcohol-related societal harm approximates to £21 billion per annum. 8 In the USA, the proportion of adults consuming alcohol is lower than in the UK at 46.3%. 9 The 12-month prevalence of alcohol dependence is estimated to be 3.8% (men 5.4%; women 2.3%) while the estimated lifetime prevalence is 12.5% (men 17.4%; women 8.0%). 10 Alcohol dependence is associated with more than 85 000 deaths per year making it the third leading cause of preventable deaths in the USA; 11 the estimated annual cost to society is more than $220 billion. 12 Alcohol dependence: definitions, diagnosis and natural history A proportion of people consuming alcohol at harmful levels will develop alcohol dependence. This condition is characterised by craving; tolerance; a pre-occupation with alcohol; continued drinking in spite of harmful consequences; and the development of a physiological withdrawal syndrome when alcohol is suddenly stopped or consumption reduced. 13 More exact definitions of this condition, which is officially recognised as a mental health disorder, are provided by the World Health Organization in the International Classification of Diseases (ICD) 14 and by the American Psychiatric Association in the Diagnostic and Statistical Manual of Mental Disorders (DSM). 15 The ICD-10 and DSM-IV diagnostic criteria for alcohol dependence largely overlap and have high diagnostic concordance (Table 1) . 16 The diagnosis of alcohol dependence is usually made by reviewing the clinical history but this can be imprecise if the patient is unaware, or reluctant to reveal the extent of their problems with alcohol. However, questionnaires can facilitate the process. The Alcohol Use Disorders Identification Test (AUDIT), 17 for example, which was developed as a World Health Organization (WHO) collaborative initiative, is designed to identify people who have an alcohol use disorder; a score of ≥8 indicates hazardous/harmful drinking while a score of >16 indicates alcohol dependence. 17 Harmful alcohol use and alcohol dependence are relatively uncommon before the age of 15 but, thereafter, the prevalence increases steeply reaching a peak in the early twenties before declining. In one UK study, the prevalence of alcohol dependence was 6% in 16-19 year olds, 8 .2% in 20-24 year olds, 3.6% in 30-34 year olds, and 2.3% in 50-54 year olds. 18 Thus, substantial remission from alcohol dependence can occur, over time, often without intervention. 19 However, those who remain dependent in their forties tend to have a more chronic course; most studies find that 70-80% of people entering specialist treatment will relapse in the year after completing treatment, most likely in the first 3 months. 20, 21 Those who remain abstinent from alcohol for the first year after treatment have a relatively low risk of relapse thereafter. 22 The long-term prognosis for people entering specialist treatment is comparatively poor. Over a 10-year period about one-third have continuing alcohol problems; a third show some improvement and a third have a good outcome defined as either abstinence or moderate drinking. 23 The mortality rate in this population is nearly four times the age-adjusted rate for people who are not alcohol dependent. Much of the excess mortality is accounted for by disorders associated with comorbid tobacco use, including, cardiovascular disease and aerodigestive malignancies.
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The treatment of alcohol dependence The severity of alcohol dependence can be assessed using the Severity of Alcohol Dependence Questionnaire (SADQ); 25 the information provided can facilitates clinical management. The initial step in the treatment of alcohol dependence is withdrawal from alcohol. In some, but not all instances, medical assistance will be required to prevent or to treat the withdrawal symptoms; benzodiazepines are the drugs most commonly employed to facilitate this process. 13, 26, 27 Expert guidance on the withdrawal process, including all aspects of patient safety and general well-being, is available from the UK National Institute for Health and Care Excellence (NICE). 13, 26 People with mild dependence (SADQ score <15) do not usually need medically-assisted withdrawal; people with moderate dependence (SADQ 15-30) usually do need medical assistance, typically in a community setting; 21 while people who are severely alcohol dependent (SADQ score >30) will require medically-assisted withdrawal, typically in an in-patient or residential setting.
Withdrawal management is not a stand-alone process but should be the first phase of a long-term treatment plan. For the majority of people who are dependent on alcohol the most appropriate goal, in terms of alcohol consumption, is total abstinence. For people with significant psychiatric or physical comorbidity, for example, a depressive disorder or alcohol-related cirrhosis, abstinence should always be the goal. Nevertheless, some people will not accede to this advice, preferring a goal of moderation. However, the more severe the level of dependence the less likely it is that a return to moderate or controlled drinking will be possible. 22, 28 Thus, where a clinician believes that abstinence is the most appropriate goal they should strongly advise this course, but should not deny treatment if this advice is not heeded.
21
Psychosocial intervention is the mainstay of the treatment for alcohol dependence. 13 In the UK, NICE has provided detailed guidance on the provision of psychosocial support tailored to reflect the severity of the dependence. 13 Services are delivered by both statutory and non-statutory providers and additional sources of support, such as self-help based interventions, are encouraged. NICE also recommends the use of adjuvant pharmacotherapy for people with moderate to severe dependence once they had been successfully withdrawn from alcohol. 13 They also recommend adjuvant pharmacotherapy for people with mild dependence who have either not responded to initial all advocate the use of adjuvant pharmacotherapy, in combination with behavioural intervention or addictionfocused counselling, for the management of alcohol dependence. Finally, the Australian guidelines for the treatment of alcohol problems 33 stipulate that pharmacotherapy should be considered for all alcohol-dependent patients following detoxification -best used in association with psychosocial supports as part of an after-care treatment plan. In this review, the efficacy and safety of current and future potential pharmacotheraputic agents for the management of alcohol dependence will be assessed; their use in clinical practice will be detailed; factors predictive of treatment outcomes, including compliance and pharmacogenetics, will be delineated; and the current barriers to treatment will be explored.
METHODS
A general literature search was undertaken for articles on the generic topic 'treatment of alcohol dependence'. In addition, a specific language-unrestricted electronic search was undertaken of the Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Library, MEDLINE, EMBASE, and Science Citation Index for pharmacotherapeutic trials published between 1966 and October 2016; this was supplemented by manual searches of the bibliographies of relevant papers, specialist journals, conference proceedings and trial registries.
RESULTS
Licensed pharmacotherapies for the maintenance of abstinence Disulfiram, acamprosate and naltrexone are the only pharmaceutical agents licensed for the maintenance of abstinence/relapse prevention in dependent drinkers in the majority of countries advocating the use of pharmacotherapy for the management of alcohol dependence (Table 2 ). Nalmefene has recently been licensed, in some countries, for use in people who are drinking at high risk levels who wish to reduce their alcohol consumption but not necessarily abstain.
Disulfiram. Disulfiram has been used in clinical practice for the last 60 years; the oral preparation is licensed for relapse prevention in the UK, much of Europe, North America, Australia and parts of Asia. Despite its apparent efficacy, when used in compliant and/or supervised patients, overall its use remains controversial.
Mode of action:
Alcohol is metabolised in the liver, via the enzyme alcohol dehydrogenase, to acetaldehyde and then to acetate via the enzyme acetaldehyde dehydrogenase (ALDH). Disulfiram is an oral ALDH inhibitor. The high levels of acetaldehyde which accumulate following alcohol ingestion in people taking disulfiram result in the development of a constellation of symptoms such as flushing, nausea, vomiting, tachycardia, hypotension, dyspnoea, dizziness and headache. 34 These symptoms appear approximately 5-15 min after alcohol consumption and last from 30 min to several hours. The intensity of the reaction varies with the amount of alcohol consumed and can prove fatal. 35, 36 The fear of the unpleasant effects provoked by alcohol is believed to be the primary mechanism facilitating abstinence from alcohol. 37, 38 Disulfiram has been used in the treatment of cocaine addiction particularly in people with comorbid alcoholrelated problems. [39] [40] [41] It inhibits the enzyme dopamine b-hydroxylase, which converts dopamine to norepinephrine, and may reduce cocaine use because it inhibits the associated noradrenergic-mediated 'high'.
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Efficacy: There is no consensus on the optimal trial methodology for assessing the efficacy of disulfiram as a treatment for alcohol dependence. It has long been held that it cannot be appraised fairly in double-blind, randomised, clinical trials (RCTs) because the psychological fear of provoking an unpleasant disulfiram-alcohol reaction is key to its effectiveness.
A number of systematic reviews and meta-analyses of the available trial data have been undertaken, 13, 41, 43, 44 with a degree of consensus on treatment efficacy. The most comprehensive of these 41 41 However, no evidence of efficacy was found in blinded RCTs or where there was no supervision.
41
Safety: The side-effects associated with use of disulfiram include: headaches, drowsiness, lethargy, peripheral neuropathy, optic neuritis, hepatotoxicity and psychosis. 36, 45, 46 In general, the moderately severe sideeffect profile can be offset by careful patient selection and supervision.
Therapeutic use: There are a number of contra-indications to the use of disulfiram including: cardiovascular disease, systemic hypertension, severe personality disorder, suicidal risk/psychosis, pregnancy/breast-feeding.
Caution is also advised in the presence of renal failure, hepatic or respiratory disease, diabetes mellitus and epilepsy. NICE guidance suggests that disulfiram should be used as second-line treatment after acamprosate or naltrexone or if a strong preference for its use is expressed. 13 Treatment should be started at least 24 h after the last alcoholic drink in a dose of 200 mg per day; warnings should be provided about the nature and seriousness of the interaction with ingested alcohol and the presence of alcohol in foodstuffs, perfumes and aerosol sprays. Supervision should be sought whenever possible. Treatment, if successful and relatively free from side-effects, may be continued long term.
Acamprosate. Acamprosate was introduced into clinical practice 30 years ago; the oral preparation is licensed for the maintenance of abstinence in alcohol-dependent people in a wide range of countries including the UK, most of Europe, North America, Australia, parts of Asia and Africa and, most recently, Japan. Mode of action: Acamprosate is the calcium salt of N-acetyl-homotaurine. Its mechanism of action is unclear although it has been ascribed to aspects of glutamatergic and/or GABA-ergic neurotransmission; it is most frequently referred to as a 'functional glutamate antagonist'. 47 Recently, however, it has been suggested that acamprosate has no direct neurotransmitter target and that the therapeutic effects associated with its use are due to the co-administered calcium moiety. 48, 49 These findings have yet to be substantiated but the role of plasma and/or brain levels of calcium as a correlate or mediating factor in relation to the drug's efficacy may need to be further explored.
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Efficacy:
The results of a large number of RCTs and meta-analyses 13, 44, [50] [51] [52] [53] have shown that treatment with acamprosate, in conjunction with psychosocial support, significantly increases the proportion of alcohol-dependent patients who remained completely abstinent from alcohol at 6 months. Mann et al., 50 in a meta-analysis of 17 RCTs, involving 4087 participants, showed that 36.1% of patients receiving acamprosate achieved this endpoint compared with 23.4% of those receiving placebo; overall the number needed to treat (NNT) to achieve continuous abstinence was 7.8 at 6 months and 7.5 at 12 months.
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A Cochrane review, including 24 RCTs with 6915 participants, 51 showed a significant beneficial effect of acamprosate on a number of outcome measures other than abstinence; thus, its use was associated with a reduction in the return to any drinking with a NNT of nine; a reduction in the risk of any drinking to 86% of the placebo rate and an increase in the number of abstinent days by approximately three per month.
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Safety: Acamprosate is not metabolised in the liver and has no impact on drugs subject to hepatic metabolism or those which affect the cytochrome P450 system. Thus, it does not interact with alcohol and it is generally safe in patients with impaired hepatic function. However, as it is excreted predominantly via the kidney, it should be used with care in people with renal insufficiency. Acamprosate is well-tolerated. 46 Pharmacovigilance data in 1.5 million patients indicate no serious adverse events; 54 the most commonly reported side-effect is diarrhoea. 50 It does not have addictive potential and appears safe in overdose. 47 Therapeutic use: Acamprosate is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min) and in those who are hypersensitive to the drug or any of its components. Guidelines in the UK, 13 France, 29 the USA, 30, 31 and Australia 33 recommend that acamprosate is used as firstline treatment for alcohol dependence. It should be started as soon as possible after assisted withdrawal from alcohol in a daily divided dose of 1998 mg in people weighing >60 kg and of 1332 mg in those weighing <60 kg. 13 There is no need to adjust the dose in people with mild to moderate hepatic impairment, although dose adjustment is recommended in people with moderate renal impairment. 13 Treatment should continue for 6 months or longer in those deriving benefit who wish to continue; it can be continued if patients lapse but should be stopped if drinking persists beyond 4-6 weeks. 13 Naltrexone. Naltrexone has been used in the management of opioid dependence since 1984; it was first used to treat alcohol dependence in 1994. The oral preparation is licensed for relapse prevention in alcohol-dependent people in a wide range of countries including the UK, much of Europe, the USA, Australia and Asia.
Mode of action: Naltrexone and its active metabolite 6b-naltrexol act as opioid receptor antagonists, particularly at the l-opioid receptor. Its excretion is primarily renal. The mechanism of its beneficial effect in the treatment of alcohol dependence is not fully understood although it is believed to reduce the reward effects of alcohol by modulating the dopaminergic mesolimbic pathway.
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Efficacy: A substantial number of RCTs have been undertaken to examine the efficacy of naltrexone for the treatment of alcohol dependence. These have been the subject of a number of systematic reviews and meta-analyses employing varying inclusion criteria and drinking outcomes but, nevertheless, with broadly comparable results. 13, 44, 52, 54, [57] [58] [59] Thus, in alcohol-dependent people who have been withdrawn from alcohol, naltrexone, in combination with psychosocial support, has a modest, albeit significant beneficial effect on relapse rates, and in reducing alcohol intake. A Cochrane systematic review and meta-analysis, including 40 placebo-controlled RCTs of naltrexone, involving approximately 4500 participants, showed that treatment with naltrexone significantly reduced the risk of a return to heavy drinking to 83% of the placebo rate with a NNT of nine. 58 Treatment was also associated with a 4% reduction in the number of drinking days; a 3% reduction in the number of heavy drinking days; and a reduction in the amount of alcohol consumed, on drinking days, by about 11 g. It did not, however, have a significant effect on the return to any drinking. 58 The effect on overall abstinence rates was not determined. The results of a number of other meta-analyses confirm the effects of naltrexone in reducing the risk of a relapse to heavy drinking and the number of drinks consumed on drinking days; [57] [58] [59] some found that its use was, in addition, associated with a significant, albeit modest effect on the return to any drinking and overall abstinence rates.
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Safety: Naltrexone is metabolised in the liver via the enzyme dihydrodiol dehydrogenase predominantly to 6b-naltrexol; the metabolites are further conjugation with glucuronide. As naltrexone is not metabolised via the cytochrome P450 system interactions with drugs subject to hepatic metabolism are likely to be minimal. However, increased plasma naltrexone concentrations have been reported in patients with cirrhosis. Naltrexone does not interact with alcohol and does not have addictive potential.
The most commonly reported side-effects are nausea, vomiting, dizziness, abdominal pain, reduced appetite, headache and daytime sleepiness; these are dose-dependent and appear to be worse in women. 46 Hepatotoxicity has been reported in association with use of naltrexone in doses of >300 mg/day to treat obesity. 60 However, reviews of the available safety data have confirmed that hepatic toxicity is very unlikely to occur with the standard daily dose of 50 mg. 13 The most important safety consideration in relation to naltrexone is its reaction with opioid drugs. Opioid receptor blockade persists for 48-72 h after the last oral dose; thus, in an emergency non-opioid analgesia would have to be used for pain relief. If future use of opioids is anticipated, for example, for elective surgery, then naltrexone should be discontinued ahead of time.
Therapeutic use: Naltrexone is contraindicated in individuals taking or likely to take opioids. It is also contraindicated in people with acute hepatitis and acute or chronic liver failure. It should be used with caution in people with serum transaminase activities exceeding three times the upper reference range and in patients with renal failure. At present, there is no consistent advice about monitoring of liver function tests in people receiving this drug but NICE guidance recommends that this should be considered in the elderly and the obese and that the drug should be discontinued immediately if the user feels unwell. 13 Guidelines in the UK, 13 France, 29 the USA, 30, 31 and Australia 33 recommend that naltrexone should be considered as a first-line treatment for alcohol dependence. Opioids should be stopped 7-10 days beforehand but treatment can be started while patients are still drinking and during medically-assisted withdrawal from alcohol. An initial dose of 25 mg/day is recommended increasing over a period of 2 weeks to a maintenance dose of 50 mg/day. 13 Treatment should be continued for 6 months or longer in those deriving benefit who wish to continue; it can be continued if patients lapse but should be stopped if drinking persists beyond 4-6 weeks.
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Combined treatment with acamprosate and naltrexone. The effect sizes of acamprosate and naltrexone are modest and hence the effect of combining the two treatments has been explored. 61, 62 Keifer et al., 61 randomised 160 severely dependent drinkers to acamprosate, naltrexone, acamprosate/naltrexone combined or placebo for 12 weeks; all participants received specific relapse prevention intervention. Both acamprosate and naltrexone and their combination had a positive treatment effect relative to placebo; the naltrexone/acamprosate combination was more effective than acamprosate alone but comparable in effect to naltrexone alone. Anton et al., 62 randomised 1383 much less severely dependent drinkers to the same four arms of treatment for 16 weeks; participants were further randomised to receive one of two different types of behavioural therapy. Outcomes improved in all participant groups but were significantly better in those receiving naltrexone together with intensive behavioural therapy; combining treatments had no additional beneficial effect. Meta-analysis of these two trials confirmed that there were no significant differences in outcome favouring combined treatment. 13, 58 Co-administration of acamprosate and naltrexone results in a 33% increase in the peak plasma concentrations of acamprosate and a reduction in the time to reach peak plasma levels but has no effect on the pharmacokinetics of naltrexone. Thus, the incidence of diarrhoea and nausea was, as expected, significantly higher in the combined treatment groups, in both trials. 58, 61, 62 Nalmefene. Nalmefene is an opioid system modulator which is structurally similar to naltrexone but it has a slightly different receptor profile. It was first introduced into clinical practice for the treatment of alcohol dependence in the early 1990s. [63] [64] [65] However, a metaanalysis of the three RCTs available from that time, which utilised daily doses in the 20-80 mg range, showed that although nalmefene had some beneficial effect on drinking outcomes none of these was significant. 58 Subsequently, the drug was remarketed and licensed, on the basis of a small number of additional industrysponsored initiatives, [66] [67] [68] [69] [70] for use in people who were drinking harmfully and wanted to reduce, though not necessarily stop, their alcohol consumption. However, this so called 'harm reduction' approach to alcohol problems remain controversial. 71 Thus, although several studies have demonstrated that controlled drinking is possible and that moderation-based treatments may be preferred over abstinence-only approaches, the evidence base for using this approach is not strong. there was some evidence of a beneficial effect of nalmefene on the number of heavy drinking days per month and on total alcohol consumption but there were more withdrawals for safety reasons in the nalmefene-treated groups and the findings were not robust. There was no evidence of a beneficial effect of nalmefene on the health outcomes examined. The authors concluded that, at best, nalmefene has limited efficacy in reducing alcohol consumption but they were clearly aware of the limitations of their review and made specific recommendations for future studies.
The licensing and subsequent recommendations for the therapeutic use of nalmefene have been widely criticised. 75, 76 The major objections raised include: (i) the target population was defined following an unplanned subgroup analysis of the available trials, thus departing from the intention-to-treat principle; (ii) the placebo comparator was inappropriate -the efficacy of nalmefene should have been compared with naltrexone which is used off-label for this indication; (iii) the supposed advantage conferred by nalmefene on alcohol consumption levels was of questionable clinical relevance; and, (iv) no evidence of wider harm reduction was sought or provided in the trials included for review. As nalmefene is an opioid receptor antagonist the same precautions and guidance provided for naltrexone in relation to opioid usage should apply. The most commonly encountered side-effects are nausea, insomnia, dizziness, vomiting and fatigue. However, use of naltrexone has not been associated with evident hepatotoxicity. Naltrexone is considerably more expensive than the other drugs licensed to treat alcohol dependence, at least in the UK.
Emerging treatments for alcohol dependence
A number of other agents have been proposed and are currently under investigation as potential treatment options for alcohol dependence. [77] [78] [79] [80] [81] [82] The majority already have a therapeutic profile and are being repurposed for use in this field. Of these baclofen, topiramate and metadoxine are the best known, but others with an evidence base include: (i) gabapentin: an inhibitor of presynaptic, voltage-gated sodium and calcium channels which is approved for the treatment of epilepsy and neuropathic pain; (ii) ondansetron: a serotonin 5-HT3 receptor antagonist which is used to prevent nausea and vomiting in selected clinical situations; (iii) varenicline: a nicotinic receptor partial agonist which is used for smoking cessation; and, (iv) aripiprazole: an anti-psychotic which is a partial dopamine agonist. None of these compounds is licensed for the treatment of alcohol dependence but can of course be used off-label.
Baclofen. Baclofen is a selective c-aminobutyric acid (GABA)-B receptor agonist which was originally approved for the treatment of spasticity associated with multiple sclerosis and spinal cord lesions. Activation of GABA-B receptors might reduce anxiety and it was for this reason that it was identified as a potential treatment for alcohol withdrawal and dependence. A number of placebo-controlled RCTs of baclofen, 30-60 mg/day, have been undertaken but with widely different results. [83] [84] [85] [86] [87] [88] A series of trials undertaken by one Italian group, [83] [84] [85] including a trial in patients with cirrhosis, 84 showed significantly higher abstinence rates in participants receiving baclofen compared with placebo, together with improvements in other drinking outcomes. 83, 85 However, studies undertaken in the USA, 86 Australia 87 and Israel 88 showed no beneficial effects of baclofen over placebo on any drinking outcome, although a post hoc analysis of the Australian data showed that baclofen conferred some benefit, in terms of relapse behaviour, in a subgroup of patients with a comorbid anxiety disorder. 87 Overall the drug was welltolerated. The divergent results of these studies have not been fully explained. One suggestion is that they may relate to the relatively low doses of baclofen used in the trials undertaken to date. Baclofen is rapidly absorbed and excreted primarily unchanged by the kidney but there is significant inter-subject variation in its pharmacokinetics, which could potentially be reflected in differences in population responses. This view was supported by the self-reported experience of a French physician who treated his own alcohol dependence and anxiety disorder with baclofen in a dose of 270 mg/day. 89, 90 The consequent media interest resulted in an unprecedented demand, in France, for off-label treatment with high dose baclofen. 91, 92 In 2014, baclofen, in doses up to 300 mg/day, was authorised by the French Health Agency (FHA) as a second-line drug to prevent relapse or reduce drinking in people with alcohol dependence 93 This authorisation, which is a specific measure known as a 'temporary recommendation for use' (TRU) requires centralised collection of follow-up data. 93 Studies utilising high doses of baclofen are now being reported. A German group randomised 56 alcoholdependent people to either baclofen titrated to 270 mg/ day or placebo. 94 The mean daily dose of baclofen achieved during the 12 week high dose phase of the trial was 180 mg and during this phase abstinence rates were higher in those receiving baclofen than placebo (68.2% vs. 23.8%, P = 0.014); baclofen also had a significant beneficial effect on overall abstinence rates during the 20 week trial (42.9% vs. 14.3% P = 0.04). However, there was no relationship between the individualised doses of baclofen and drinking behaviour outcomes suggesting that the efficacy of baclofen does not have a clear dose threshold.
A multicentre RCT 95 undertaken in the Netherlands randomly assigned 151 alcohol-dependent individuals to 6 weeks titration and 10 weeks maintenance with either low-dose baclofen (30 mg/day), high-dose baclofen (up to 150 mg/day; mean 94 mg/day), or placebo. No significant differences were observed between the groups in the time to first relapse; the proportions who relapsed; the proportions who attained continuously abstinence; the cumulative abstinence duration; or the drop-out rates. Two important considerations need to be taken into account in relation to this trial viz: (i) the drug dosage schedule and degree of psychosocial support differed between patients recruited from inpatient and outpatient facilities; and, (ii) the continuous abstinent rates were very high viz. high dose baclofen 62.5% cf. placebo 65.9%. The results of two French high-dose baclofen studies, which will be pivotal in determining whether the TUR currently in place will be removed by the FHA or made official, have been reported but in abstract form only. 96, 97 In the first of these -the ALPADIR study 96 -320 alcohol-dependent out-patients attending French specialist alcohol treatment clinics were randomised to baclofen (target dose 180 mg/day attained by 66%) or placebo using a 7-week titration, and 17 weeks maintenance paradigm. The proportions of patients who were continuously abstinent throughout the trial were similar in both groups viz. baclofen 11.9%; placebo 10.5%. Post hoc subgroup analyses showed more evidence of benefit in the heaviest drinkers and when the outcome variable selected was the overall reduction in consumption. The second of these French studies -the multicenter BACLOVILLE study -was designed to explore pragmatic risk reduction in a general practice. 98 A total of 320 attendees diagnosed as having an alcohol use disorder were randomised to treatment with baclofen, individually titrated to a maximum dose of 300 mg/day, or placebo for 12 months. There was no requirement for participants to be withdrawn from alcohol or to receive psychosocial support. The primary outcome, which was the proportion of patients who achieved WHO defined safe drinking levels (1-20 g/day for women and 1-40 g/day for men) was attained by 56.8% of the baclofen group and 36.5% of the placebo group (risk reduction 1.56 [95% CI: 1.15-2.11]; P = 0.004). At present, no other information on outcome variables or safety is available. 98 These four high-dose baclofen studies are not directly comparable as they differ considerably in aspects of patient selection; study design and duration; dosage schedules; and outcome variables. In addition, the reporting of the two French studies is still incomplete. Thus, overall conclusions about the efficacy of baclofen as a treatment for alcohol dependence cannot be made at this time.
Baclofen and alcohol are both central nervous depressants so there are considerable safety concerns around use of this drug. 46 Fatigue, sleep disorders and vertigo/ dizziness were more frequent in those taking the active drug particularly in the high-dose studies. Reports of further adverse event such as major sedation, 99 a separate analysis of six placebo-controlled RCTs of topiramate, involving 970 participants, and showed a modest but significant beneficial effect on heavy drinking and the number of drinks per drinking day but a rather less robust effect on the number of abstinent days. Topiramate in a dose of 300 mg/day appears to be relatively well-tolerated with the most common adverse effects being dizziness, paraesthesia and anorexia. However, all the trials undertaken to date are short-term; with long-term treatment there is potential, given the drug's safety profile, for the emergence of other side-effects such as difficulties with memory and cognitive impairment.
Metadoxine. Metadoxine (pyridoxal L-2-pyrrolidone-5-carboxylate) is an ion pair salt of pyridoxine and L-pyroglutamate. It is approved in several European countries, India, the Russian Federation and Brazil for treating acute alcohol intoxication, based on its ability, when given as a single 900 mg intravenous dose, to facilitate the elimination of alcohol from blood and tissues. 105 Metadoxine has also been used to treat alcohol dependence based on its properties as a selective serotonin receptor subtype 5-HT 2B antagonist and a monoamineindependent GABA modulator. 106 In an open-label study, patients treated with metadoxine, 1500 mg/day in divided doses, were significantly more likely to maintain abstinence at 3 months than untreated controls (44.8% vs. 21.6%; P < 0.004). 107 In a randomised, open-label study in patients with severe alcoholic hepatitis survivors who received metadoxine, in addition to standard therapy, were significantly more likely to maintain abstinence at 6 months than those who did not (74.5% vs. 59.4%, P = 0.02).
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Metadoxine has an excellent safety record. 109 Its use needs to be further explored.
Pharmacotherapy in specific situations
Alcohol-related liver disease. The most important management goal for patients with significant alcohol-related liver injury is abstinence from alcohol. Nevertheless, this aspect of their management, and in particular, the use of adjuvant pharmacotherapy to achieve this goal, is inconsistently addressed in the literature with scant or no mention by some 110, 111 but specific mention by others. [112] [113] [114] No RCTs of the three main medications currently licensed for the treatment of alcohol dependence have been undertaken in people with significant alcoholrelated liver injury. Of these, acamprosate has the best safety profile. 46, 51, 54 It is not metabolised in the liver and there are no reported instances of hepatotoxicity. Furthermore, Delgrange et al., 115 reported, in a single dose RCT, that acamprosate does not adversely affect neuropsychiatric status in patients with Child's Grade A and B cirrhosis. Hepatotoxicity has not emerged as a clinical problem with naltrexone in standard doses, although hepatotoxicity is a concern, in certain circumstances, when higher doses are used. 60 Patients with advanced liver disease are particularly vulnerable to naltrexone-induced hepatotoxicity, 116 so its use in this situation would need to be montored carefully. Use of disulfiram has been complicated by the development of hepatotoxicity which is associated with a mortality rate of 28%. 117 It is best avoided in patients with chronic liver disease. Baclofen in a dose of 30 mg/day has been shown, in one RCT, to be a safe and effective treatment for alcohol dependence in patients with cirrhosis. 84 However, the study population was very carefully selected to exclude people with diabetes, hepatic encephalopathy, psychiatric comorbidity and comorbid drug misuse. Hence, the safety findings in this study may not be generalisable. In addition, much higher doses of baclofen are now being used to treat alcohol dependence but no information is available on the safety profile associated with these dose levels in patients with liver disease; until this information is available considerable caution should be exercised in use of this drug in this setting. Topiramate has only rarely been linked to clinically apparent liver injury. However, as it is metabolised via CYP3A4 it may potentiate the hepatotoxicity associated with other drugs metabolised via this system. The anti-epileptic drug sodium valproate, for example, inhibits the first enzyme in the urea cycle and its use may be associated with the development of hyperammonaemic encephalopathy; co-medication with topiramate increases the circulating levels of free valproate and significantly increases the risk of this potentially fatal complication. 118 Metadoxine has an excellent safety profile and has been shown to have utility not only to treat alcohol dependence but also alcohol-related liver disease. It accelerates the normalisation of liver function tests and the liver appearance on ultrasound in individuals with alcohol-related steatosis, even in those who do not completely abstinent from alcohol. 119 In patients with severe alcoholic hepatitis treated with prednisolone the addition of metadoxine significantly improved survival, compared with prednisolone alone, both at 30 days (74.3% vs. 45.7%; P = 0.02) and at 90 days (68.6% vs. 20.0%; P = 0.0001). 120 The addition of metadoxine also significantly reduced the development/progression of hepatic encephalopathy (29.6% vs. 60.0%; P = 0.008) and hepatorenal syndrome (31.4% vs. 54.3%; P = 0.05). 120 These beneficial effects likely relate to the fact that metadoxine is an antioxidant and has also been shown to inhibit hepatic lipid accumulation and protect against glutathione depletion. 121 Further studies with this drug are clearly needed. Both the American and European Associations for the Study of the Liver 122, 123 recommend the use of acamprosate and naltrexone, in conjunction with psychosocial support, to decrease the likelihood of relapse in patients with alcohol-related liver disease. Future recommendations with regard to the use of baclofen in this setting will require a more extensive evidence base.
Comorbid psychiatric disorders and co-occurring drug misuse. Psychiatric comorbidity and co-occurring drug misuse are common in people with alcohol dependence. However, pharmacological intervention for alcohol dependence, in these situations, has received very little attention. 13 People with alcohol dependence are frequently anxious and/or depressed but these symptoms often remit once they achieve abstinence or significantly reduce their alcohol intake. 13 Medication for depression and anxiety is often ineffective in people who are consuming significant amounts of alcohol either for relieving the psychiatric symptoms or for curbing the alcohol misuse. 124, 125 In consequence, guidance from NICE recommends focusing on the management of the alcohol misuse as the first priority. 13 Acamprosate can be used to facilitate abstinence under these circumstances; it is well-tolerated; it does not interact with alcohol or have addictive potential; and is safe in overdose. Naltrexone and disulfiram both interact with alcohol and are less safe in these situations. If, however, symptoms of significant anxiety or depression remain after 3-4 weeks of abstinence from alcohol then patients should be referred appropriately for specific management of their mental health disorder. 126 People with alcohol dependence and significant comorbid mental problems, such as schizophrenia or bipolar disorder, and those assessed to be at high risk of suicide, should be referred to a psychiatrist to make sure that effective assessment, treatment and risk-management plans are put in place. 127 Alcohol and illicit drug dependence often co-occur. Treatment of the drug misuse must be optimised using psychosocial and/or pharmacological approaches, as appropriate, 128 but the alcohol misuse must also be specifically addressed. Naltrexone is not an option in individuals who have used or are using opioids and there are no published studies of acamprosate in opioiddependent populations. Nevertheless, acamprosate is safe, well-tolerated and does not interact with the commonly used illicit drugs or with methadone or the anti-viral agents use to treat comorbid hepatitis C or HIV infection.
Predictors of outcome
The drugs currently available for the treatment of alcohol dependence have only modest effects and attempts have been made to optimise treatment by identifying people more likely to respond. These attempts are confounded by the so-called 'placebo effect' and by factors pertaining to adherence and compliance with treatment.
The placebo effect. The placebo effect can confound efforts to determine treatment effectiveness in clinical trials. The greater the placebo group response the more difficult it is to demonstrate medication efficacy. The placebo response in trials of drugs for alcohol dependence appears to be even greater than, for example, trials in depression and schizophrenia. Furthermore, more recent studies in alcohol dependence have shown greater placebo group improvement, an effect which persists even after controlling for several other moderators, including concomitant interventions. Thus, attempts will need to be made to more effectively isolate alcohol medication effects in future studies.
129, 130
Compliance and adherence. The clinical effectiveness of any medication is highly influenced by the degree of patient compliance and adherence to treatment regimens. Trials of drugs for the treatment of alcohol dependence, as in the addiction field generally, are characterised by high drop-out rates and generally low levels of compliance with treatment. 42, 51, 58 However, very little information is available on the factors which affect compliance in this setting. Rohsenow et al., 131 found that compliance with naltrexone was better in those who believed that the medication would help them maintain abstinence, and was not predicted by demographic or pre-treatment alcohol use, commitment to abstinence or perceptions about their own ability to abstain. Supervision or witnessing, which are employed primarily in patients receiving disulfiram, are a major determinant of compliance and hence effectiveness. 42 Demography, drinking variables and comorbidities. A number of demographic variables, along with features of the drinking behaviour and potential comorbidities, have been explored and several possible predictors of outcome identified, but the results are inconsistent. The most favourable results in people receiving unsupervised disulfiram were in those who were older; more socially stable; impulsive and motivated. 34, 132 Pooled data from seven placebo-controlled RCTs of acamprosate, involving 1485 participants, showed that there were no significant relationships between treatment outcome and gender, the age of onset, the severity of dependence or family history. 133 A number of studies have reported that people with a family history of alcohol-related problems are more likely to benefit from naltrexone but other identified predictors such as high levels of craving, early age of onset, concomitant drug misuse and comorbid depression are not as robust. 134 142, 143 explored the relationship between the outcomes of treatment with topiramate and polymorphisms in the glutamate ionotropic receptor kainate type subunit 1 (GRIK1) gene, which encodes the GluK1 subunit of the glutamatergic kainate receptor. In alcohol-dependent people who were homozygous for the C allele in rs2832407 treatment with topiramate resulted in a greater reduction in alcohol consumption than in carriers of the A allele. It has been suggested that homozygosity for the C allele moderates peoples' desire to drink and increases their belief in their ability to abstain. 142, 143 The serotonin transporter (5-HTT) is encoded by the gene, solute carrier family 6 member 4 (SLC6A4). The promotor region of SLC6A4 contains a polymorphism with short (S) and long (L) repeats in a 5 0 -HTT-linked polymorphic region (5 0 -HTTLPR). Johnson et al., 144 showed that individuals homozygous for the L allele had better drinking outcomes, following treatment with ondansetron, than carriers of the S allele.
No studies have been undertaken, to date, to assess the clinical utility of genotype-guided medication selection or dosing strategies, and in only one, which was unfortunately substantially underpowered, were participants randomised to treatment with naltrexone or placebo by genotype. 145 Future studies may ultimately define a range of genetic variations that have clinical value in predicting response to the drugs used to treat alcohol dependence.
Barriers to treatment Between 1.6 and 3.2 million people in England are alcohol dependent. 2, 3 In 2014-2015 only 150 640 (4.7-9.4%) of those affected received specialist treatment for their alcohol problems and this was only successfully completed in an estimated 47 900. 146 However, despite the fact that pharmacotherapy has been shown to be cost-effective this treatment approach is significantly underutilised. 13 Thus, in 2015, only 196 000 items were prescribed in primary care and NHS hospital settings throughout England although separate data were not available for naltrexone as it is also prescribed for drug use disorders. Overall acamprosate accounted for 71% of the prescribed items while nalmefene accounted for 2.2%. 146 While overall there has been a steady increase in the number of items dispensed this remains small given the size of the population at risk (Figure 1 ). Recent data from Australia show that only 3% of people with alcohol dependence receive pharmacotherapy and, of those, only 15-25% receive the minimum period of 3 months treatment recommended in the National Guidelines. 147 There are several possible barriers to the use of pharmacotherapy for the treatment of alcohol dependence (Table 3) . Thus, for example, doctors may be reluctant to prescribe because they lack knowledge of or familiarity with the products available, 148 while certain statutory and non-statutory agencies may be reluctant to prescribe on philosophical grounds or simply because they are not able to (Table 3) .
There are also other broader issues. Thus, the development of pharmaceutical agents to treat alcohol use disorders is hampered by an incomplete understanding of the neurobiological background of alcohol dependence and inconsistent results from genome wide association studies which have, overall, failed to identify robust, replicable targets for drug development. Further investigation and investment is clearly needed.
CONCLUSION
Individuals with alcohol use disorders often fail to receive care, particularly evidence-based care, and there is clear evidence that although drug treatment for alcohol dependence is safe and cost-effective it is substantially underutilised. Efforts must be made to overcome the current barriers to treatment which, in large part, reflect unwillingness by doctors to prescribe these medications.
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